Essays & Notes
Writing
Essays on oncology commercialization, market access, launch strategy, and clinical development — the strategic questions I keep returning to, worked out in full.
The Placebo Arm Problem: Why Second-Entrant Trials May Overstate Superiority
Once a first-in-class drug is approved, the remaining patients eligible for the second entrant's trial are different. Enrollment-era bias means placebo arms in sequential trials are not comparable — and cross-trial superiority claims built on that foundation are weaker than they appear.
Why Oral Formulations Don't Always Win: The Part B Economics That Favor Infusion Incumbents
Conventional pharma wisdom assumes oral beats injectable. But Part B buy-and-bill economics create financial incentives for community oncologists to maintain infusion-based prescribing — and the patient cost math can actually favor the needle.
Underdiagnosis Is the Real Competitor: Why Rare Disease Launches Fail Before They Start
In rare disease, the standard launch playbook assumes the market exists. But when class penetration is below 30%, the majority of eligible patients are undiagnosed. The real competitor isn't the incumbent drug — it's diagnostic inertia.
Why PharmDs Should Learn to Code
The gap between clinical expertise and technical execution is the single biggest bottleneck in oncology commercialization. Here's how to close it.